Kira Raskina

Senior Research Technician at Vall d'Hebron Institute of Oncology (VHIO)

Kira Raskina is an accomplished data analyst and research professional with diverse experience across multiple prestigious organizations. Currently serving as a Data Analyst at Sanofi and a Senior Research Technician at the Vall d'Hebron Institute of Oncology, Kira has previously held impactful roles including Data Scientist at Foundation Medicine and Clinical Trial Investigator at Novo Nordisk. Kira's background includes extensive data handling, algorithm development, and clinical consultation related to endocrine disorders, complemented by a strong educational foundation with a Master of Science in Biostatistics from Brown University and a Doctor of Medicine from Lomonosov Moscow State University.

Location

Barcelona, Spain

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Vall d'Hebron Institute of Oncology (VHIO)

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.


Industries

Headquarters

Spain

Employees

201-500

Links